重组人血管内皮抑制素注射液联合化疗治疗晚期非小细胞肺癌疗效探讨  

Efficacy of Recombinant Human Endostatin Injection Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：金萍艳 

机构地区：[1]内蒙古呼伦贝尔市传染病医院肿瘤内科,内蒙古呼伦贝尔162650

出　　处：《中国继续医学教育》2017年第5期145-147,共3页China Continuing Medical Education

摘　　要：目的探讨重组人血管内皮抑制素注射液联合化疗治疗晚期非小细胞肺癌的临床疗效。方法选取2015年2月—2016年5月本院收治的68例晚期非小细胞肺癌患者作为研究对象,随机分为对照组和观察组,各34例。对照组常规采用NP方案治疗,观察组采用重组人血管内皮抑制素注射液联合NP方案治疗,比较两组化疗治疗效果,并监测两组患者毒副反应情况。结果观察组化疗近期有效率(64.71%,22/34)高于对照组(38.24%,13/34),组间差异有统计学意义,P<0.05。观察组毒副反应发生率(14.71%,5/34)低于对照组(35.29%,12/34),组间差异有统计学意义,P<0.05。结论晚期非小细胞肺癌常规NP化疗方案基础上联合重组人血管内皮抑制素注射液治疗,可进一步提升近期疗效,且改善了化疗安全性。Objective To investigate the clinical efficacy of recombinant human endostatin injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods 68 cases of advanced non-small cell lung cancer patients were chosen as the research object from February 2015 to May 2016 in our hospital, were randomly divided into control group and observation group, 34 cases each. The control group was treated with NP regimen, the observation group was treated with recombinant human endostatin injection combined with NP regimen, and the effects of two groups were compared, and the adverse reactions of the two groups were monitored. Results Observation group recent effective chemotherapy （64.71%, 22/34） was significantly higher than that of control group （38.24%, 13/34）, the difference between group P〈0.05. Incidence of adverse reaction observation group （14.71%, 5/34） was significantly lower than the control group （35.29%, 12/34）, the difference between groups, P〈0.05. Conclusion Advanced non small cell lung cancer NP based conventional chemotherapy combined with endostar in treatment of recombinant human endostatin injection, will further enhance the curative effect, and improve the safety of chemotherapy.

关 键 词：重组人血管内皮抑制素注射液 化疗 晚期非小细胞肺癌 安全性 临床疗效 

分 类 号：R734[医药卫生—肿瘤]